Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896827 | 0.81 | SIGMAR1 (0.36) | KDM1AAKR1B1RAD52 | |
| SCHEMBL3910550 | 0.81 | KDM1A (0.53) | KDM1ASLC6A3SLC6A4 | |
| SCHEMBL1333907 | 0.78 | KDM1A (0.47) | KDM1ACYP3A4AKR1B1 | |
| SCHEMBL6567499 | 0.77 | KDM1A (0.48) | KDM1ACYP3A4 | |
| SCHEMBL8613008 | 0.76 | AR (0.33) | KDM1ASLC6A3SLC6A4HDAC4 | |
| SCHEMBL11086002 | 0.74 | KDM4C (0.35) | KDM1ASLC6A3SLC6A4CYP17A1CYP3A4 | |
| SCHEMBL7568312 | 0.74 | AKR1B1 (0.41) | KDM1AAKR1B1HDAC4 | |
| SCHEMBL30558325 | 0.73 | APP (0.39) | KDM1ACYP17A1CYP3A4CYP11B2CYP11B1 | |
| SCHEMBL17361959 | 0.73 | APP (0.39) | KDM1ACYP17A1CYP3A4CYP11B2CYP11B1 | |
| SCHEMBL11079385 | 0.72 | SLC6A3 (0.42) | SLC6A3SLC6A4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1403256-A1 | FUSED IMIDAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | KDM1A 2636/4885SLC6A3 3131/4885SLC6A4 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.